President Donald Trump has signed an executive order aimed at expediting the FDA's review process for certain psychedelics designated as breakthrough therapy drugs. The order seeks to remove bureaucratic hurdles, enhance data sharing among federal agencies, and facilitate quicker rescheduling of approved substances, including those showing promise for mental health treatment.

Trump highlighted the potential of these treatments to revolutionize mental health care, especially for veterans suffering from severe depression and trauma. He cited research from Stanford University indicating significant symptom reduction in veterans treated with ibogaine and announced a $50 million federal investment in ongoing research, matching Texas state funding. The order also opens pathways for administering promising psychedelics under the right-to-try law, aiming to offer hope to patients with debilitating conditions.

This move underscores a historic shift towards faster medical innovations in psychedelics, driven by promising early research and a focus on mental health crisis solutions. As clinical trials advance, the administration emphasizes safety and efficacy, hoping these treatments can provide life-changing benefits for those in need.